Wells Fargo Downgrades Arcus Biosciences to Equal-Weight, Lowers Price Target to $23
Benzinga Newsdesk 9 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Wells Fargo analyst Eva Fortea Verdejo downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to Equal-Weight and lowers the price target from $30 to $23.
Wells Fargo analyst Eva Fortea Verdejo downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to Equal-Weight and lowers the price target from $30 to $23.